Critical Path Institute Announces New CEO Critical Path Institute (C-Path) announced today that Dr. Carolyn Compton has joined the organization as its new president and chi
European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
C-Path Recognized in One of The National Institute of Mental Health’s Top 10 Research Advances of 2011
Critical Path Institute and Hamner Institutes for Health Sciences Announce Collaboration to Improve Safety of Medical Product Development Critical Path Institute(C-Path)and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a
January 12, 2011 Patient Self-report for Evaluating Mild Cognitive Impairment and Prodromal Alzheimer’s Disease
Critical Path Institute Gathers Cross-Sector Innovators at Global Conference on Drug Development Hundreds of leaders from cross-sector arenas in government, academia, the biotechnology and pharmaceutical industry, and patient a
CPTR Yields Progress: New Five-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Sanofi, Tibotec, TB Alli
The Patient-Reported Outcome Consortium: Filling Measurement Gaps for PRO End Points to Support Labeling Claims
Brian Harvey, VP, U.S. Regulatory Policy at Sanofi, speaks on panel at Partnering for Cures Nov. 8, 2011 Highlights benefits of public-private partnerships like C-Path’s Coalition Against Major Diseases (CAMD): Stresses importanc